b>j)΄!Pԫ&;"kB޶}pSVT(wę!j x;-m@JnQ+պכ7MajfJͱ4jѲ撆RxZMz7vIW/dٞТזcZM~ji ߒsQzԠDW3Den"M+/B:-uIJ7j委9p='mANޭ=/B:-n&nUfqxZM~c Ϲ+,&ᾺܢF[(1*" ϒ"Jԧ<;b" "jܢF[x ,!q қ*]/؝27SMcs"ޭDQ/应ܢF_! :s" 7`F+SVTn"IJnQ/应B 4 wD"IJ׭-`S9DrjiEJ߅gJ应矁[xZM~n"IB؃!'Тѕ+(mIKʭ/|ϐܢF[xZMzG %嬩/c[[\n

Tagrisso is a <\/span>third-generation tyrosine kinase inhibitor<\/b><\/span> designed to target epidermal growth factor receptor (EGFR) mutations, helping <\/span>control the growth of cancer cells<\/b><\/span> in NSCLC. This <\/span>advanced therapy<\/b><\/span> offers proven benefits, including <\/span>longer progression-free survival<\/b><\/span> and improved overall outcomes compared to earlier EGFR inhibitors.<\/span><\/p>\n

Tagrisso is <\/span>available in dose options<\/b><\/span> designed to match your treatment plan and your doctor\u2019s prescription:<\/span><\/p>\n